Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials
Cancer originating in the biliary tract can be classified as bile duct cancer (cholangiocarcinoma), gallbladder cancer, or ampullary cancer. Bile duct cancer is further divided to intrahepatic, perihilar and distal bile duct subtypes according to the anatomical location of the tumor. The biological...
Uloženo v:
| Vydáno v: | Japanese journal of clinical oncology Ročník 50; číslo 12; s. 1353 |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
16.12.2020
|
| Témata: | |
| ISSN: | 1465-3621, 1465-3621 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Cancer originating in the biliary tract can be classified as bile duct cancer (cholangiocarcinoma), gallbladder cancer, or ampullary cancer. Bile duct cancer is further divided to intrahepatic, perihilar and distal bile duct subtypes according to the anatomical location of the tumor. The biological characteristics of each tumor are heterogeneous. However, because of the rarity of each disease, the efficacy of new drugs has been tested in groups of patients with different biliary tract cancers. In patients with metastatic or recurrent biliary tract cancer, recent randomized clinical trials revealed the non-inferiority of gemcitabine + S-1 and the superiority of gemcitabine + cisplatin + S-1 compared with gemcitabine + cisplatin in terms of overall survival, thereby establishing a new standard treatment. In the field of adjuvant therapy for biliary tract cancer, the British BILCAP (capecitabine compared with observation in resected biliary tract cancer) study revealed longer median overall survival in the capecitabine group than in the observation group in the per-protocol analysis (but not in the intention-to-treat analysis), bringing a shift toward postoperative management. Several other studies of adjuvant therapy are ongoing, and they may lead to reforms in treatment strategy for resectable biliary tract cancer in the future. The use of neoadjuvant therapy for biliary tract cancer is in its infancy, but it is expected to overcome the limitations of adjuvant therapy for this malignancy. In this review, we summarized the evidence available from clinical trials of adjuvant and neoadjuvant therapy for biliary tract cancer and described ongoing clinical trials. |
|---|---|
| AbstractList | Cancer originating in the biliary tract can be classified as bile duct cancer (cholangiocarcinoma), gallbladder cancer, or ampullary cancer. Bile duct cancer is further divided to intrahepatic, perihilar and distal bile duct subtypes according to the anatomical location of the tumor. The biological characteristics of each tumor are heterogeneous. However, because of the rarity of each disease, the efficacy of new drugs has been tested in groups of patients with different biliary tract cancers. In patients with metastatic or recurrent biliary tract cancer, recent randomized clinical trials revealed the non-inferiority of gemcitabine + S-1 and the superiority of gemcitabine + cisplatin + S-1 compared with gemcitabine + cisplatin in terms of overall survival, thereby establishing a new standard treatment. In the field of adjuvant therapy for biliary tract cancer, the British BILCAP (capecitabine compared with observation in resected biliary tract cancer) study revealed longer median overall survival in the capecitabine group than in the observation group in the per-protocol analysis (but not in the intention-to-treat analysis), bringing a shift toward postoperative management. Several other studies of adjuvant therapy are ongoing, and they may lead to reforms in treatment strategy for resectable biliary tract cancer in the future. The use of neoadjuvant therapy for biliary tract cancer is in its infancy, but it is expected to overcome the limitations of adjuvant therapy for this malignancy. In this review, we summarized the evidence available from clinical trials of adjuvant and neoadjuvant therapy for biliary tract cancer and described ongoing clinical trials.Cancer originating in the biliary tract can be classified as bile duct cancer (cholangiocarcinoma), gallbladder cancer, or ampullary cancer. Bile duct cancer is further divided to intrahepatic, perihilar and distal bile duct subtypes according to the anatomical location of the tumor. The biological characteristics of each tumor are heterogeneous. However, because of the rarity of each disease, the efficacy of new drugs has been tested in groups of patients with different biliary tract cancers. In patients with metastatic or recurrent biliary tract cancer, recent randomized clinical trials revealed the non-inferiority of gemcitabine + S-1 and the superiority of gemcitabine + cisplatin + S-1 compared with gemcitabine + cisplatin in terms of overall survival, thereby establishing a new standard treatment. In the field of adjuvant therapy for biliary tract cancer, the British BILCAP (capecitabine compared with observation in resected biliary tract cancer) study revealed longer median overall survival in the capecitabine group than in the observation group in the per-protocol analysis (but not in the intention-to-treat analysis), bringing a shift toward postoperative management. Several other studies of adjuvant therapy are ongoing, and they may lead to reforms in treatment strategy for resectable biliary tract cancer in the future. The use of neoadjuvant therapy for biliary tract cancer is in its infancy, but it is expected to overcome the limitations of adjuvant therapy for this malignancy. In this review, we summarized the evidence available from clinical trials of adjuvant and neoadjuvant therapy for biliary tract cancer and described ongoing clinical trials. Cancer originating in the biliary tract can be classified as bile duct cancer (cholangiocarcinoma), gallbladder cancer, or ampullary cancer. Bile duct cancer is further divided to intrahepatic, perihilar and distal bile duct subtypes according to the anatomical location of the tumor. The biological characteristics of each tumor are heterogeneous. However, because of the rarity of each disease, the efficacy of new drugs has been tested in groups of patients with different biliary tract cancers. In patients with metastatic or recurrent biliary tract cancer, recent randomized clinical trials revealed the non-inferiority of gemcitabine + S-1 and the superiority of gemcitabine + cisplatin + S-1 compared with gemcitabine + cisplatin in terms of overall survival, thereby establishing a new standard treatment. In the field of adjuvant therapy for biliary tract cancer, the British BILCAP (capecitabine compared with observation in resected biliary tract cancer) study revealed longer median overall survival in the capecitabine group than in the observation group in the per-protocol analysis (but not in the intention-to-treat analysis), bringing a shift toward postoperative management. Several other studies of adjuvant therapy are ongoing, and they may lead to reforms in treatment strategy for resectable biliary tract cancer in the future. The use of neoadjuvant therapy for biliary tract cancer is in its infancy, but it is expected to overcome the limitations of adjuvant therapy for this malignancy. In this review, we summarized the evidence available from clinical trials of adjuvant and neoadjuvant therapy for biliary tract cancer and described ongoing clinical trials. |
| Author | Esaki, Minoru Ioka, Tatsuya Ban, Daisuke Furuse, Junji Nara, Satoshi Ishii, Hiroshi Okusaka, Takuji Shimada, Kazuaki Takamoto, Takeshi |
| Author_xml | – sequence: 1 givenname: Satoshi surname: Nara fullname: Nara, Satoshi organization: Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan – sequence: 2 givenname: Minoru surname: Esaki fullname: Esaki, Minoru organization: Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan – sequence: 3 givenname: Daisuke surname: Ban fullname: Ban, Daisuke organization: Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan – sequence: 4 givenname: Takeshi surname: Takamoto fullname: Takamoto, Takeshi organization: Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan – sequence: 5 givenname: Kazuaki surname: Shimada fullname: Shimada, Kazuaki organization: Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan – sequence: 6 givenname: Tatsuya surname: Ioka fullname: Ioka, Tatsuya organization: Oncology Center, Yamaguchi University Graduate School of Medicine, 1-1-1 Minami Kogushi Ube-shi, Yamaguchi, 755-8505, Japan – sequence: 7 givenname: Takuji surname: Okusaka fullname: Okusaka, Takuji organization: Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan – sequence: 8 givenname: Hiroshi surname: Ishii fullname: Ishii, Hiroshi organization: Division of Gastroenterology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, Chiba, 260-8717, Japan – sequence: 9 givenname: Junji surname: Furuse fullname: Furuse, Junji organization: Department of Medical Oncology, Kyorin University Faculty of Medicine, 6-20-2 Shinkawa, Mitaka-shi, Tokyo, 181-8611, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33037430$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkM1Lw0AQxRep2A-9eZY9eondr2wSb6X4BQUv6jVMJrt0Q7qpm6TS_94FW_AwvBn48Xhv5mTiO28IueXsgbNCLpsGu-X2CMAzdkFmXOk0kVrwyb99SuZ93zDG0lxlV2QqJZOZkmxGvlZ1Mx7ADxR8Tb3p4HwPWxNgf6S2C7RyrYNwpEMAHCiCRxMeKdBgDs780M5SbJ13CG1EHLT9Nbm0UczNSRfk8_npY_2abN5f3tarTYIqZ0OCEhGrTFTa2BiNaZshK7iss1rpnCNLjdXSqhTzOJoboepKYG4QcwHKigW5__Pdh-57NP1Q7lyPpm0hVhn7UihVFGnBmIro3Qkdq52py31wu9ipPP9C_ALvG2PL |
| CitedBy_id | crossref_primary_10_1016_j_heliyon_2024_e41356 crossref_primary_10_7759_cureus_64116 crossref_primary_10_1002_jso_27112 crossref_primary_10_1002_jhbp_12143 crossref_primary_10_1016_j_ejso_2023_107324 crossref_primary_10_4240_wjgs_v17_i8_108160 crossref_primary_10_1186_s12957_024_03596_y crossref_primary_10_3390_cancers13163996 crossref_primary_10_1016_j_omto_2022_10_004 crossref_primary_10_1093_jjco_hyab190 crossref_primary_10_4251_wjgo_v16_i1_13 crossref_primary_10_5306_wjco_v16_i4_102374 crossref_primary_10_1007_s00104_021_01453_2 crossref_primary_10_1007_s10147_022_02165_1 crossref_primary_10_3389_fonc_2022_834104 crossref_primary_10_1016_j_heliyon_2024_e32528 crossref_primary_10_1186_s12876_024_03266_z crossref_primary_10_1089_ten_tec_2022_0193 crossref_primary_10_1093_jjco_hyaa205 crossref_primary_10_1155_2022_1427779 crossref_primary_10_3389_ti_2022_10802 crossref_primary_10_1245_s10434_021_09961_5 crossref_primary_10_3390_cancers17091450 crossref_primary_10_1080_17474124_2021_1911645 crossref_primary_10_1186_s12935_024_03548_2 crossref_primary_10_1097_SLA_0000000000005016 crossref_primary_10_1002_jcla_24103 crossref_primary_10_1016_j_hbpd_2021_12_005 crossref_primary_10_1093_jjco_hyad104 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| Copyright_xml | – notice: The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1093/jjco/hyaa170 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1465-3621 |
| ExternalDocumentID | 33037430 |
| Genre | Journal Article Review |
| GroupedDBID | --- -E4 .2P .I3 .ZR 0R~ 18M 1TH 29J 2WC 4.4 482 48X 5GY 5RE 5VS 5WA 5WD 70D AABZA AACZT AAJKP AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABNHQ ABNKS ABPTD ABQLI ABQNK ABVGC ABWST ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFRAH AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CGR CS3 CUY CVF CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS ECM EE~ EIF EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IH2 IOX J21 KAQDR KBUDW KOP KQ8 KSI KSN M-Z M49 MHKGH ML0 N9A NGC NOMLY NOYVH NPM O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PQQKQ Q1. Q5Y RD5 RHF ROX ROZ RUSNO RW1 RXO TCURE TEORI TJX TR2 W8F WOQ X7H YAYTL YKOAZ YXANX ZKX ~91 7X8 ABPQP ADNBA AEMQT AHGBF AJBYB AJNCP ALXQX JXSIZ |
| ID | FETCH-LOGICAL-c480t-c3cccb72b6ef58406f7c0913d7d4681c05ef63f45c845c61e24db2c8ecc82a4f2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 34 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000605982500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1465-3621 |
| IngestDate | Thu Oct 02 12:07:43 EDT 2025 Wed Feb 19 02:30:31 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 12 |
| Keywords | biliary tract cancer carcinoma of the ampulla of Vater gallbladder cancer bile duct cancer cholangiocarcinoma |
| Language | English |
| License | The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c480t-c3cccb72b6ef58406f7c0913d7d4681c05ef63f45c845c61e24db2c8ecc82a4f2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://academic.oup.com/jjco/article-pdf/50/12/1353/34925273/hyaa170.pdf |
| PMID | 33037430 |
| PQID | 2449959004 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2449959004 pubmed_primary_33037430 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-Dec-16 |
| PublicationDateYYYYMMDD | 2020-12-16 |
| PublicationDate_xml | – month: 12 year: 2020 text: 2020-Dec-16 day: 16 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Japanese journal of clinical oncology |
| PublicationTitleAlternate | Jpn J Clin Oncol |
| PublicationYear | 2020 |
| SSID | ssj0005847 |
| Score | 2.442801 |
| SecondaryResourceType | review_article |
| Snippet | Cancer originating in the biliary tract can be classified as bile duct cancer (cholangiocarcinoma), gallbladder cancer, or ampullary cancer. Bile duct cancer... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1353 |
| SubjectTerms | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biliary Tract Neoplasms - classification Biliary Tract Neoplasms - drug therapy Biliary Tract Neoplasms - pathology Biliary Tract Neoplasms - surgery Capecitabine - therapeutic use Chemotherapy, Adjuvant Cisplatin - therapeutic use Clinical Trials as Topic Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Drug Combinations Humans Neoadjuvant Therapy Oxonic Acid - therapeutic use Tegafur - therapeutic use |
| Title | Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33037430 https://www.proquest.com/docview/2449959004 |
| Volume | 50 |
| WOSCitedRecordID | wos000605982500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5qRbz4ftQXEbyGbrJpEr1IEYsHW3rQ0lvJThK0h93a3Qr99yb7oCdB8LCBPeySzAyTSb75ZhC6o4kzgoIlidZQwoxE8ZgRR7URknOAsk3n-FUOh2oyuR_VF255nVbZ-MTSUZsMwh15x29DoTSW1-nj_IuErlEBXa1baGyiVuxDmZDSJSfrauEBAqzYRV3iHTWtE9_9Ib4zm0HW-VhpTWX0e3BZbjL9_f9O7wDt1eEl7lX2cIg2bHqEdgY1gH6Mxj0zW_rgucA6NTi1mW7eKyLWCvsgFoeEWb1Y4SJQqDAEw1g8YI0rngvOHG4Ilbjs-pGfoPf-89vTC6lbKxDgKioIxACQSJYI67yUIuEkhAqhRhouFIWoa52IHe-C8o-glnGTMFBe4Ypp7tgp2kqz1J4jzEFo6RiNdZTwyCTK_yVxYBW4yHhNt9FtI7GpN92AR2i_vGU-Xcusjc4qsU_nVY2NaRyHwjhxdPGHry_RLgunYMoIFVeo5fy67TXahu_iM1_clDbhx-Fo8APen8P7 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Adjuvant+and+neoadjuvant+therapy+for+biliary+tract+cancer%3A+a+review+of+clinical+trials&rft.jtitle=Japanese+journal+of+clinical+oncology&rft.au=Nara%2C+Satoshi&rft.au=Esaki%2C+Minoru&rft.au=Ban%2C+Daisuke&rft.au=Takamoto%2C+Takeshi&rft.date=2020-12-16&rft.issn=1465-3621&rft.eissn=1465-3621&rft.volume=50&rft.issue=12&rft.spage=1353&rft_id=info:doi/10.1093%2Fjjco%2Fhyaa170&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1465-3621&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1465-3621&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1465-3621&client=summon |